{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T05:27:45Z","timestamp":1676006865482},"reference-count":24,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antitumor activities of L-MTP-PE (Liposome entrapped myuramyl tripeptide phosphatidylethanolamine) in the combination treatment with chemo- or immune-therapeutic antitumor agents against various syngeneic tumors were tested.<\/jats:p><jats:p>Against Meth A fibrosarcoma solid tumor system, L-MTP-PE showed slight but statistically significant elongation of survival days against 5-FU monotherapy in spite of its non-effect on tumor growth, when combined with 5-FU. Against liver metastasis model of M5076 carcinoma, L-MTP-PE showed a tendency of elongation of survival days by its single drug treatment, however, elongation with statistical significance was observed in the combination treatment with 5-FU in comparison with control group.<\/jats:p><jats:p>These data suggest that L-MTP-PE seems to elongate the survival days of the solid tumor bearing mice and the liver metastasis model basically due to its saving effect on chemotherapeutic drug-induced immunosuppression. In the combination with an immunotherapeutic agent in mice, TNF production induced by another biological response modifier OK-432 was potentiated when primed with L-MTP-PE. L-MTP-PE also potentiate the antitumor effect of OK-432 possibly through the enhanced production of TNF-\u03b1. Combination of L-MTP-PE and OK-432 is considered to be a candidate for a new treatment model for cancer.<\/jats:p>","DOI":"10.1055\/a-1847-7312","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T22:43:27Z","timestamp":1656542607000},"page":"372-377","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Liposome-Entrapped Muramyl Tripeptide Phosphatidylethanolamine (L-MTP-PE) on the Tumor Growth and Survival of Mice Bearing Syngeneic Tumor in Combination with a Chemotherapeutic or Immunomodulatory Agent"],"prefix":"10.1055","volume":"72","author":[{"given":"Motoharu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Health and Nutrition, Faculty of Human Science, Tokiwa University, Mito, Ibaraki, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Abe","sequence":"additional","affiliation":[{"name":"Teikyo University Institute of Medical Mycology, Hachioji, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/0006-291X(74)90458-6","article-title":"Minimal structured requirements for adjuvant activity of bacterial peptidoglycan derivatives","volume":"59","author":"F Ellouz","year":"1974","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.4049\/jimmunol.135.2.1372","article-title":"Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice","volume":"135","author":"W E Fogler","year":"1985","journal-title":"J. Immunol."},{"key":"ref4","first-page":"43","article-title":"Efficacy of liposome containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages","volume":"1","author":"I J Fidler","year":"1982","journal-title":"In Vivo. J. Biol. Resp. Modif"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00200032","article-title":"A dried preparation of liposomes containing muramyl tripeptide phosphatidyletyhanolamine as a potent activator of human blood monocytes to the antitumor state","volume":"22","author":"S Sone","year":"1986","journal-title":"Cancer Immunol. Immunother."},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.4049\/jimmunol.135.2.1477","article-title":"Augmentation of NK cell activity in tissues specific sites by liposomes incorporating MTP-PE","volume":"135","author":"J E Talmadge","year":"1985","journal-title":"J. Immunol."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jnci\/81.12.935","article-title":"Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide","volume":"81","author":"E G MacEwen","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF00199357","article-title":"Optimization and limitation of systemic treatment of murine melanoma metastasis with liposomes containing muramyl tripeptide phosphatidylethanolamine","volume":"21","author":"IJ Fidler","year":"1986","journal-title":"Cancer Immunol. Immunother."},{"key":"ref9","first-page":"986","article-title":"Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice","volume":"38","author":"R Nakajima","year":"1988","journal-title":"Arzneim.-Forsch. Drug Res."},{"key":"ref10","first-page":"92","author":"H Oshima","year":"1985","journal-title":"Theoretical grounds and practical methods for induction of endogenous production of human tumor necrosis factor. In \u201cHost defense mechanisms against cancer (Urushizaki, I., Aoki, T and Tsubura, E. eds). Excerpta Medica, Amsterdam, pp"},{"key":"ref11","first-page":"564","article-title":"Priming effect of orally administered muramyl dipeptide (MDP) on induction of endogenous of tumor necrosis factor (TNF)","volume":"9","author":"H Okutomi","year":"1990","journal-title":"J. Biol. Response Mod."},{"key":"ref12","first-page":"97","article-title":"Induction of tumor necrosis factor-\u03b1in solid tumor region by the orally administered synthetic muramyl dipeptide analogue, romurtide","volume":"1","author":"U Ueda","year":"2001","journal-title":"Inter. Immunol"},{"key":"ref13","first-page":"117","article-title":"Endogenous production of TNF in mice lung after BCG-sensitization","volume":"5","author":"M Satoh","year":"1986","journal-title":"J. Biol. Res. Modif"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/iai.31.1.380-385.1981","article-title":"Rabbit tumor necrosis factor: mechanism of action","volume":"31","author":"M R Ruff","year":"1981","journal-title":"Infect. Immun."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1084\/jem.148.6.1550","article-title":"The immunological basis of endotoxin-induced tumor regression","volume":"148","author":"M J Berendt","year":"1978","journal-title":"J. Exp. Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1002\/cncr.24566","article-title":"Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma","volume":"115","author":"J C Alexander","year":"2009","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/14656566.2011.543129","article-title":"Mifamuride for the treatment of nonmetastatic osteosarcoma","volume":"12","author":"K Ando","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref18","first-page":"118","article-title":"The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole mycobacterium bovis organisms or muramyl tripeptide","volume":"18","author":"Z Xu","year":"1984","journal-title":"Cancer Immunol. Immunother."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/00002371-199311000-00006","article-title":"Liposome-encapsulated MTP-PE: A novel biologic agent for cancer therapy","volume":"14","author":"T Asano","year":"1993","journal-title":"J. immunother."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.4049\/jimmunol.174.10.6518","article-title":"Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release","volume":"174","author":"M G Netea","year":"2005","journal-title":"J. Immunol."},{"key":"ref21","first-page":"78","article-title":"Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and toll-like receptor 4 signaling","volume":"29","author":"M Okamoto","year":"2006","journal-title":"J. Immunol."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"7803","DOI":"10.1073\/pnas.0802726105","article-title":"A NOD2-NALP1 complex mediates caspase-1-dependent IL-1\u03b2 secretion in response to Bacillus anthracis infection and muramyl dipeptide","volume":"105","author":"L C Hsu","year":"2008","journal-title":"Proc. Nat. Acad. Sci."},{"key":"ref23","first-page":"298","article-title":"Species variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenously","volume":"4","author":"I J Fidler","year":"1985","journal-title":"J. Biol. Resp. Modif"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/jps.2600821005","article-title":"Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE","volume":"82","author":"B Gay","year":"1993","journal-title":"J. Pharmac. Sci."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"S Zhu","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1847-7312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T03:15:20Z","timestamp":1675998920000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1847-7312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":24,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2022,9,6]]},"published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1847-7312","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]}}}